Skip to content
Regen Biopharmainc

Menu

Regen Biopharmainc

Menu

Author: user

July 13, 2013 08:30 ET | SOURCE: Regen BioPharma, Inc.

Bio-Matrix Scientific Group Provides Update on Its Regen BioPharma’s HemaXellerate I(TM) Clinical Program 

June 07, 2013 08:30 ET | SOURCE: Regen BioPharma, Inc.

Bio-Matrix Scientific Group’s Regen BioPharma Submits Response to FDA Questions Regarding HemaXellerate Clinical Program 

February 05, 2013 10:35 ET | SOURCE: Regen BioPharma, Inc.

Regen BioPharma Files Investigational New Drug (IND) Application With FDA on HemaXellerate I™ Stem Cell Drug for Aplastic Anemia

January 24, 2013 08:30 | SOURCE: Regen BioPharma, Inc.

Regen BioPharma Peer-Reviewed Publication Provides Preclinical Support for HemaXellerate™ Bone Marrow Failure Product

November 19, 2012 08:30 ET | SOURCE: Regen BioPharma, Inc.

Bio-Matrix’ Regen BioPharma Initiates Pre-Clinical Study in Support of HemaXellerate™ Cell Therapy

October 29, 2012 10:30 ET | SOURCE: Regen BioPharma, Inc.

June 26, 2012 08:30 ET | SOURCE: Regen BioPharma, Inc.

Bio-Matrix Scientific Group, Inc. Recruits Senior Scientist for Its Regen BioPharma Subsidiary

June 26, 2012 08:30 ET | SOURCE: Regen BioPharma, Inc.

Bio-Matrix Scientific Group, Inc. Recruits Senior Scientist for Its Regen BioPharma Subsidiary

June 15, 2012 14:32 ET | SOURCE: Regen BioPharma, Inc.

Bio-Matrix Scientific Group Announces David Audley, the Founder of International Cellular Medicine Society, Has Joined the Advisory Board of Its Regen BioPharma Subsidiary

June 07, 2012 08:30 ET | SOURCE: Regen BioPharma, Inc.

Bio-Matrix Scientific Group’s Regen BioPharma Subsidiary Executes Option Agreement to License Stem Cell Intellectual Property

← Previous
Next →
  • Founded in 2012 as a biotechnology company focused on immunotherapy and autoimmunity.
  • Fully reporting and trading under the symbols RGBP and RGBPP.
  • Currently focused on developing cellular therapies (including CAR-T cells) as well as RNA and DNA technologies for the treatment of various cancers .
  • 1 IND cleared and 2 INDs submitted with the FDA.
  • Diverse pre-clinical pipeline including platform technologies .
  • Strong intellectual property protected by multiple patents

Quick Links

  • About Us
  • Product Pipeline
  • Investor Relations
  • News
  • Careers
  • Contact Us
  • Founded in 2012 as a biotechnology company focused on immunotherapy and autoimmunity.
  • Fully reporting and trading under the symbols RGBP and RGBPP.
  • Currently focused on developing cellular therapies (including CAR-T cells) as well as RNA and DNA technologies for the treatment of various cancers .
  • 1 IND cleared and 2 INDs submitted with the FDA.
  • Diverse pre-clinical pipeline including platform technologies .
  • Strong intellectual property protected by multiple patents

Quick Links

  • About Us
  • Product Pipeline
  • Investor Relations
  • News
  • Careers
  • Contact Us
  • Founded in 2012 as a biotechnology company focused on immunotherapy and autoimmunity.
  • Fully reporting and trading under the symbols RGBP and RGBPP.
  • Currently focused on developing cellular therapies (including CAR-T cells) as well as RNA and DNA technologies for the treatment of various cancers .
  • 1 IND cleared and 2 INDs submitted with the FDA.
  • Diverse pre-clinical pipeline including platform technologies .
  • Strong intellectual property protected by multiple patents

Quick Links

  • Home
  • About Us
  • Product Pipeline
  • Investor Relations
  • News
  • Careers
  • Contact Us
Back to top

© COPYRIGHT 2023. ALL RIGHTS RESERVED.

  • Terms Of Use
  • Accessibility
Twitter
  • Founded in 2012 as a biotechnology company focused on immunotherapy and autoimmunity.
  • Fully reporting and trading under the symbols RGBP and RGBPP.
  • Currently focused on developing cellular therapies (including CAR-T cells) as well as RNA and DNA technologies for the treatment of various cancers .
  • 1 IND cleared and 2 INDs submitted with the FDA. Diverse pre-clinical pipeline including platform technologies .
  • Strong intellectual property protected by multiple patents
  • Terms Of Use
  • Accessibility

Quick Links

  • Home
  • About Us
  • Product Pipeline
  • News
  • Management Team
  • Investor Relations​
  • Contact Us
Back to top
  • Terms Of Use
  • Accessibility
Twitter

© COPYRIGHT 2023. ALL RIGHTS RESERVED.

  • Home
  • What we do
  • Product Pipeline
  • Investor Relations
  • News & Updates
  • What we do
  • Product Pipeline
  • Investor Relations
  • News & Updates

An overview of Regen BioPharma

  • About Us​
  • Management Team and Scientific Advisory Board
  • Careers 
  • Contact Us
  • Management Team and Scientific Advisory Board
  • Careers 
  • Contact Us

Our management, scientific advisory board and intellectual property

  • Product Pipeline
  • DuraCAR
  • KimerApt
  • HemaXellerate
  • dCellVax
  • tCellVax
  • DiffronC
  • DuraCAR
  • KimerApt
  • HemaXellerate
  • dCellVax
  • tCellVax
  • DiffronC

Details around our intellectual property and its development

  • Investor Relations
  • Regulatory Filings
  • Regulatory Filings

Our public filing and stock information

  • Company News
  • Featured News
  • News and Updates
  • Featured News
  • News and Updates

Our press releases and upcoming events

  • Home

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

  • About Us​

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

  • Products

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

  • Investor Relations

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

  • Company News

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

  • What we do
  • Product Pipeline
  • Investor Relations
  • News & Updates
  • What we do
  • Product Pipeline
  • Investor Relations
  • News & Updates
  • Management Team and Scientific Advisory Board
  • Careers 
  • Contact Us
  • Management Team and Scientific Advisory Board
  • Careers 
  • Contact Us
  • Regulatory Filings
  • Regulatory Filings
  • Contact us
  • Careers
  • Press Releases
  • Contact us
  • Careers
  • Legal notice
  • Cookies policy
  • Privacy policy
  • Partnership
  • Covid-19
  • Press Releases
Twitter
Home

What we do

Product Pipeline

Investor Relations

News & Updates

About Us

Management Team and Scientific Advisory Board

Careers

Contact Us

Product Pipeline

DuraCAR

KimerApt

HemaXellerate

dCellVax

tCellVax

DiffronC

Investor Relations

Regulatory Filings

Company News

Featured News

News and Updates

  • Contact us
  • Careers
  • Press Releases
Twitter
  • Contact us
  • Careers
  • Legal notice
  • Cookies policy
  • Privacy policy
  • Partnership
  • Covid-19
  • Press Releases
  • Home
  • What we do
  • Product Pipeline
  • Investor Relations
  • News & Updates
  • What we do
  • Product Pipeline
  • Investor Relations
  • News & Updates

An overview of Regen BioPharma

  • About Us​
  • Management Team and Scientific Advisory Board
  • Careers 
  • Contact Us
  • Management Team and Scientific Advisory Board
  • Careers 
  • Contact Us

Our management, scientific advisory board and intellectual property

  • Product Pipeline
  • DuraCAR
  • KimerApt
  • HemaXellerate
  • dCellVax
  • tCellVax
  • DiffronC
  • DuraCAR
  • KimerApt
  • HemaXellerate
  • dCellVax
  • tCellVax
  • DiffronC

Details around our intellectual property and its development

  • Investor Relations
  • Regulatory Filings
  • Regulatory Filings

Our public filing and stock information

  • Company News
  • Featured News
  • News and Updates
  • Featured News
  • News and Updates

Our press releases and upcoming events

  • Home

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

  • About Us​

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

  • Products

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

  • Investor Relations

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

  • Company News

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

  • What we do
  • Product Pipeline
  • Investor Relations
  • News & Updates
  • What we do
  • Product Pipeline
  • Investor Relations
  • News & Updates
  • Management Team and Scientific Advisory Board
  • Careers 
  • Contact Us
  • Management Team and Scientific Advisory Board
  • Careers 
  • Contact Us
  • Regulatory Filings
  • Regulatory Filings
  • Contact us
  • Careers
  • Press Releases
  • Contact us
  • Careers
  • Legal notice
  • Cookies policy
  • Privacy policy
  • Partnership
  • Covid-19
  • Press Releases
Twitter
Home

What we do

Product Pipeline

Investor Relations

News & Updates

About Us

Management Team and Scientific Advisory Board

Careers

Contact Us

Product Pipeline

DuraCAR

KimerApt

HemaXellerate

dCellVax

tCellVax

DiffronC

Investor Relations

Regulatory Filings

Company News

Featured News

News and Updates

  • Contact us
  • Careers
  • Press Releases
Twitter
  • Contact us
  • Careers
  • Legal notice
  • Cookies policy
  • Privacy policy
  • Partnership
  • Covid-19
  • Press Releases